Keyphrases
Multiple Myeloma
100%
Myeloma
89%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
51%
Allogeneic Bone Marrow Transplantation
49%
Graft-versus-host Disease (GvHD)
41%
Relapsed or Refractory multiple Myeloma
34%
Bortezomib
33%
Bone Marrow Transplantation
29%
Marrow
28%
First Remission
27%
Transplantation
27%
Melphalan
27%
Cyclophosphamide
26%
Autograft
26%
Autotransplantation
25%
Hematological Malignancies
24%
CD34+
24%
High-dose Melphalan
24%
Remission
24%
Acute Leukemia
23%
Granulocyte Colony-stimulating Factor (G-CSF)
23%
Acute Myeloid Leukemia
23%
Peripheral Blood Stem Cells
21%
Thalidomide
21%
Overall Survival
21%
Allogeneic Transplantation
19%
CD34+ Cells
19%
Chemotherapy
19%
Autografting
19%
High-dose Therapy
19%
Complete Remission
19%
Autologous Transplantation
18%
Cyclosporine
16%
Cell Dose
16%
Disease-free Survival
16%
High-dose Chemotherapy
16%
Total Body Irradiation
15%
Engraftment
14%
HLA-identical Sibling
13%
Stem Cells
13%
Interferon-α (IFN-α)
13%
Platelets
13%
Allograft
12%
NCCN Guidelines
12%
Allogeneic
12%
High Dose
12%
Salvage Therapy
12%
Stem Cell Transplantation
12%
CD34+ Cell Dose
12%
Refractory Myeloma
12%
Medicine and Dentistry
Multiple Myeloma
87%
Myeloma
71%
Transplantation
53%
Drug Megadose
44%
Diseases
39%
Melphalan
36%
Autotransplantation
33%
Acute Leukemia
31%
Allogenic Bone Marrow Transplantation
31%
Autograft
28%
Chemotherapy
26%
Graft Versus Host Reaction
26%
Allograft
25%
Bone Marrow Transplantation
20%
Hematologic Malignancy
20%
Overall Survival
19%
Acute Myeloid Leukemia
18%
Bortezomib
18%
Acute Lymphoblastic Leukemia
16%
Peripheral Blood Stem Cell
15%
Malignant Neoplasm
15%
Conditioning
15%
Stem Cell
14%
Arsphenamine
14%
Disease Free Survival
13%
High Dose Chemotherapy
13%
Cyclophosphamide
13%
Autologous Hematopoietic Stem Cell Transplantation
12%
Platelet
12%
Infection
11%
Thalidomide
11%
Cyclosporine
11%
Stem Cell Therapy
11%
Maintenance Chemotherapy
11%
Leukemia
10%
Karyotype
10%
Engraftment
10%
Autologous Bone Marrow Transplantation
10%
Neutrophil
10%
Spontaneous Remission
9%
Salvage Therapy
9%
Induction Chemotherapy
9%
Whole Body Radiation
9%
Immunotherapy
9%
Adverse Event
9%
Event Free Survival
9%
Oncology
9%
Vincristine
9%
T Cell
9%
Methotrexate
9%
Immunology and Microbiology
Multiple Myeloma
81%
Drug Megadose
56%
CD34
38%
Overall Survival
30%
Allograft
30%
Graft-Versus-Host Disease
29%
Myeloid
28%
Allogeneic Bone Marrow Transplantation
27%
Peripheral Blood Stem Cell
24%
Cyclophosphamide
23%
Autotransplantation
22%
Bone Marrow Transplantation
19%
Stem Cell
17%
Autograft
17%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Engraftment
16%
Thalidomide
16%
Stem Cell Transplantation
15%
Ciclosporin
15%
Event Free Survival
14%
Autologous Hematopoietic Stem Cell Transplantation
12%
Interferon Type I
12%
Immunotherapy
12%
Conditioning
12%
Myeloma Protein
11%
Dexamethasone
11%
Proteasome
11%
Hematopoietic Stem Cell Transplantation
11%
Platelet
10%
Hematopoietic Cell
10%
Methylprednisolone
10%
Disease Free Survival
9%
Chronic Graft Versus Host Disease
9%
Body Weight
9%
Acute Graft Versus Host Disease
8%
Granulocyte Colony-Stimulating Factor
8%
Neutrophil Granulocyte
8%
Neutrophil
8%
Leukocyte
8%
Leukocyte Count
7%
Kidney Function
7%
Leukapheresis
7%
Lenalidomide
7%
T Cell
6%
Stem Cell Transplant
6%
Methotrexate
6%
Immunoglobulin A
5%
Growth Factor
5%
Light Chain
5%
Blood Group ABO Incompatibility
5%